A detailed history of Arizona State Retirement System transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Arizona State Retirement System holds 22,769 shares of RLAY stock, worth $144,810. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,769
Previous 22,193 2.6%
Holding current value
$144,810
Previous $244,000 22.95%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$7.5 - $12.07 $4,320 - $6,952
576 Added 2.6%
22,769 $188,000
Q4 2023

Jan 24, 2024

SELL
$6.01 - $11.48 $1,887 - $3,604
-314 Reduced 1.4%
22,193 $244,000
Q3 2023

Nov 06, 2023

BUY
$8.24 - $12.97 $2,851 - $4,487
346 Added 1.56%
22,507 $189,000
Q2 2023

Aug 01, 2023

SELL
$9.99 - $18.27 $6,073 - $11,108
-608 Reduced 2.67%
22,161 $278,000
Q1 2023

Apr 27, 2023

BUY
$15.0 - $22.76 $10,785 - $16,364
719 Added 3.26%
22,769 $375,000
Q4 2022

Feb 07, 2023

BUY
$14.16 - $24.02 $61,355 - $104,078
4,333 Added 24.46%
22,050 $329,000
Q3 2022

Nov 07, 2022

BUY
$18.07 - $31.37 $2,005 - $3,482
111 Added 0.63%
17,717 $396,000
Q2 2022

Jul 28, 2022

BUY
$13.31 - $34.88 $78,848 - $206,629
5,924 Added 50.71%
17,606 $295,000
Q1 2022

May 04, 2022

BUY
$20.26 - $32.36 $5,693 - $9,093
281 Added 2.46%
11,682 $350,000
Q4 2021

Feb 04, 2022

BUY
$26.0 - $37.03 $67,444 - $96,055
2,594 Added 29.45%
11,401 $350,000
Q3 2021

Nov 12, 2021

BUY
$29.75 - $37.99 $6,128 - $7,825
206 Added 2.4%
8,807 $278,000
Q2 2021

Aug 02, 2021

BUY
$27.5 - $38.19 $20,432 - $28,375
743 Added 9.46%
8,601 $315,000
Q1 2021

May 06, 2021

BUY
$32.52 - $61.53 $1,008 - $1,907
31 Added 0.4%
7,858 $272,000
Q4 2020

Jan 28, 2021

BUY
$35.51 - $54.03 $277,936 - $422,892
7,827 New
7,827 $325,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $765M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Arizona State Retirement System Portfolio

Follow Arizona State Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Arizona State Retirement System with notifications on news.